Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells Journal Article

Authors: Geyer, M. B.; Brentjens, R. J.
Article Title: Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Abstract: The past several years have been marked by extraordinary advances in clinical applications of immunotherapy. In particular, adoptive cellular therapy utilizing chimeric antigen receptor (CAR)-modified T cells targeted to CD19 has demonstrated substantial clinical efficacy in children and adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and durable clinical benefit in a smaller subset of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or B-cell non-Hodgkin lymphoma (B-NHL). Early-phase clinical trials are currently assessing CAR T-cell safety and efficacy in additional malignancies. Here, we discuss clinical results from the largest series to date investigating CD19-targeted CAR T cells in B-ALL, CLL, and B-NHL, including discussion of differences in CAR T-cell design and production and treatment approach, as well as clinical efficacy, nature of severe cytokine release syndrome and neurologic toxicities, and CAR T-cell expansion and persistence. We additionally review the current and forthcoming use of CAR T cells in multiple myeloma and several solid tumors and highlight challenges and opportunities afforded by the current state of CAR T-cell therapies, including strategies to overcome inhibitory aspects of the tumor microenvironment and enhance antitumor efficacy. © 2016
Keywords: acute lymphoblastic leukemia; cytokine release syndrome; adoptive cellular therapy; chimeric antigen receptors; car t cells
Journal Title: Cytotherapy
Volume: 18
Issue: 11
ISSN: 1465-3249
Publisher: Elsevier Science Ltd.  
Date Published: 2016-11-01
Start Page: 1393
End Page: 1409
Language: English
DOI: 10.1016/j.jcyt.2016.07.003
PROVIDER: scopus
PMCID: PMC5067198
PUBMED: 27592405
Notes: Review -- Export Date: 6 December 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Renier J Brentjens
    280 Brentjens
  2. Mark Blaine Geyer
    62 Geyer